keyword
MENU ▼
Read by QxMD icon Read
search

Amikacin inhalation

keyword
https://www.readbyqxmd.com/read/29914950/antibacterial-activity-of-human-simulated-epithelial-lining-fluid-concentrations-of-ceftazidime-avibactam-alone-or-in-combination-with-amikacin-inhale-bay41-6551-against-carbapenem-resistant-pseudomonas-aeruginosa-and-klebsiella-pneumoniae
#1
Safa S Almarzoky Abuhussain, Joseph L Kuti, David P Nicolau
The role of inhalational combination therapy when treating carbapenem resistant Pseudomonas aeruginosa and Klebsiella pneumoniae with newer beta-lactam/beta-lactamase inhibitors has not been established. Using a 72 hour in vitro pharmacodynamic chemostat model, we simulated the human exposures achieved in epithelial lining fluid (ELF) following intravenous ceftazidime-avibactam (CZA) 2.5g q8h alone and in combination with inhaled amikacin (AMK) 400mg q12h, a reformulated aminoglycoside designed for inhalational administration, against 3 P...
June 18, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29872328/defining-the-potency-of-amikacin-against-escherichia-coli-klebsiella-pneumoniae-pseudomonas-aeruginosa-and-acinetobacter-baumannii-derived-from-chinese-hospitals-using-clsi-and-inhalation-based-breakpoints
#2
Joseph L Kuti, Qi Wang, Hongbin Chen, Henan Li, Hui Wang, David P Nicolau
Objectives: We report the in vitro activity of amikacin and comparators against Gram-negative bacteria collected from blood and respiratory specimens in China during a 1-year period between December 2015 and December 2016. Materials and methods: Minimum inhibitory concentrations (MICs) were determined by agar dilution methods using Clinical and Laboratory Standards Institute (CLSI) guidelines, and susceptibility was assessed using CLSI breakpoints, except for tigecycline against Enterobacteriaceae...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29867826/amikacin-liposome-inhalation-suspension-alis-penetrates-non-tuberculous-mycobacterial-biofilms-and-enhances-amikacin-uptake-into-macrophages
#3
Jimin Zhang, Franziska Leifer, Sasha Rose, Dung Yu Chun, Jill Thaisz, Tracey Herr, Mary Nashed, Jayanthi Joseph, Walter R Perkins, Keith DiPetrillo
Non-tuberculous mycobacteria (NTM) cause pulmonary infections in patients with structural lung damage, impaired immunity, or other risk factors. Delivering antibiotics to the sites of these infections is a major hurdle of therapy because pulmonary NTM infections can persist in biofilms or as intracellular infections within macrophages. Inhaled treatments can improve antibiotic delivery into the lungs, but efficient nebulization delivery, distribution throughout the lungs, and penetration into biofilms and macrophages are considerable challenges for this approach...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29661870/amikacin-inhalation-as-salvage-therapy-for-refractory-nontuberculous-mycobacterial-lung-disease
#4
Byung Woo Jhun, Bumhee Yang, Seong Mi Moon, Hyun Lee, Hye Yun Park, Kyeongman Jeon, O Jung Kwon, Jungmin Ahn, Il Joon Moon, Sung Jae Shin, Charles L Daley, Won-Jung Koh
Although guidelines recommend amikacin (AMK) inhalation therapy for difficult-to-treat nontuberculous mycobacterial lung disease (NTM-LD), data are limited regarding the safety and clinical efficacy of this salvage therapy. We retrospectively evaluated treatment outcomes of 77 patients with refractory NTM-LD caused by Mycobacterium abscessus complex (MABC) or M. avium complex (MAC) who initiated AMK inhalation therapy between February 2015 and June 2016. MABC was the most common etiology (n = 48, 62%), followed by MAC (n = 20, 26%) and mixed infections (n = 9, 12%)...
April 16, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29564361/positive-effect-of-liposomal-amikacin-for-inhalation-on-mycobacterium-abcessus-in-cystic-fibrosis-patients
#5
Davide Caimmi, Nicolas Martocq, Delphine Trioleyre, Catherine Guinet, Sylvain Godreuil, Thomas Daniel, Raphael Chiron
Mycobacterium abscessus is difficult to eradicate. At the Montpellier CF Center, we prescribed liposomal amikacin for inhalation to 5 patients with M abscessus infection. The 3 patients who completed the treatment did not have any respiratory exacerbation, showed negative cultures for M abscessus in their sputum, and stabilized their spirometric functions.
March 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29562340/pharmacodynamics-of-inhaled-amikacin-bay-41-6551-studied-in-an-in-vitro-pharmacokinetic-model-of-infection
#6
Karen E Bowker, Alan R Noel, Sharon Tomaselli, Marie Attwood, Alasdair P MacGowan
Background: The pharmacodynamics of inhaled antimicrobials are poorly studied. Amikacin is being developed for inhalational therapy as BAY 41-6551. Objectives: We employed an in vitro pharmacokinetic model to study the pharmacokinetics/pharmacodynamics of amikacin. Methods: A dose-ranging design was used to establish fAUC/MIC and fCmax/MIC targets for static, -1 log drop and -2 log drop effects for strains of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa...
March 19, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29470253/management-of-nontuberculous-mycobacterial-pulmonary-disease
#7
Mark H Adelman, Doreen J Addrizzo-Harris
PURPOSE OF REVIEW: To highlight recent original research and specialty society guidelines regarding the diagnosis and treatment of nontuberculous mycobacterial (NTM) pulmonary disease. RECENT FINDINGS: The prevalence of NTM pulmonary disease has risen in recent years. The prevalence of individual NTM species varies geographically, although Mycobacterium avium complex (MAC) and Mycobacterium abscessus complex (MABC) remain among the most commonly encountered in many regions...
May 2018: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/29346118/mycobacterium-avium-complex-pulmonary-disease-new-epidemiology-and-management-concepts
#8
Leah Lande, Jason George, Theodore Plush
PURPOSE OF REVIEW: The prevalence of Mycobacterium avium complex (MAC)-related pulmonary disease has been increasing because of environmental factors, changes in organism virulence, and evolving host susceptibility. Treatment is often complicated by adverse effects, development of drug resistance, and refractory disease, with recurrence rates as high as 25-45%. RECENT FINDINGS: Aerosolization of water, soil, or dusts are the likely sources of MAC-related pulmonary disease in susceptible individuals...
April 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29098998/the-emergence-of-multidrug-resistant-pseudomonas-aeruginosa-in-cystic-fibrosis-patients-on-inhaled-antibiotics
#9
Atqah AbdulWahab, Khalid Zahraldin, Mazen A Sid Ahmed, Sulieman Abu Jarir, Mohammed Muneer, Shehab F Mohamed, Jemal M Hamid, Abubaker A I Hassan, Emad Bashir Ibrahim
INTRODUCTION: Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is an important and growing issue in the care of patients with cystic fibrosis (CF), and a major cause of morbidity and mortality. OBJECTIVE: The objective of the study was to describe the frequency of MDR-PA recovered from the lower respiratory samples of pediatric and adult CF patients, and its antibiotic resistance pattern to commonly used antimicrobial agents including β-lactams, aminoglycosides, and fluoroquinolones...
November 2017: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/29058607/aerosol-delivery-during-invasive-mechanical-ventilation-a-systematic-review
#10
Jonathan Dugernier, Stephan Ehrmann, Thierry Sottiaux, Jean Roeseler, Xavier Wittebole, Thierry Dugernier, François Jamar, Pierre-François Laterre, Gregory Reychler
BACKGROUND: This systematic review aimed to assess inhaled drug delivery in mechanically ventilated patients or in animal models. Whole lung and regional deposition and the impact of the ventilator circuit, the artificial airways and the administration technique for aerosol delivery were analyzed. METHODS: In vivo studies assessing lung deposition during invasive mechanical ventilation were selected based on a systematic search among four databases. Two investigators independently assessed the eligibility and the risk of bias...
October 21, 2017: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/28854668/current-and-future-therapies-for-pseudomonas-aeruginosa-infection-in-patients-with-cystic-fibrosis
#11
REVIEW
Wynne D Smith, Emmanuelle Bardin, Loren Cameron, Claire L Edmondson, Katie V Farrant, Isaac Martin, Ronan A Murphy, Odel Soren, Andrew R Turnbull, Natasha Wierre-Gore, Eric W Alton, Jacob G Bundy, Andrew Bush, Gary J Connett, Saul N Faust, Alain Filloux, Paul S Freemont, Andrew L Jones, Zoltan Takats, Jeremy S Webb, Huw D Williams, Jane C Davies
Pseudomonas aeruginosa opportunistically infects the airways of patients with cystic fibrosis and causes significant morbidity and mortality. Initial infection can often be eradicated though requires prompt detection and adequate treatment. Intermittent and then chronic infection occurs in the majority of patients. Better detection of P. aeruginosa infection using biomarkers may enable more successful eradication before chronic infection is established. In chronic infection P. aeruginosa adapts to avoid immune clearance and resist antibiotics via efflux pumps, β-lactamase expression, reduced porins and switching to a biofilm lifestyle...
August 1, 2017: FEMS Microbiology Letters
https://www.readbyqxmd.com/read/28813621/improvement-of-an-in-vitro-model-to-assess-delivered-dose-and-particle-size-for-a-vibrating-mesh-nebulizer-during-mechanical-ventilation
#12
Nani Kadrichu, Derek Daniher
BACKGROUND: In an in vitro model of mechanical ventilation with gravity-dependent filter position we observed artificially high delivered doses resulting from liquid droplet collection and precipitation of aerosolized drug. We sequentially modified the model to obtain accurate reproducible measurements of delivered dose and particle size at endotracheal tube exit. METHODS: Stepwise changes in the model included (1) altering the endotracheal tube position to a gravity-independent position, (2) adding fluid traps, (3) humidifying air near the test lung, and (4) simplifying test lung and filters...
April 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/28793869/the-efficacy-safety-and-feasibility-of-inhaled-amikacin-for-the-treatment-of-difficult-to-treat-non-tuberculous-mycobacterial-lung-diseases
#13
Kazuma Yagi, Makoto Ishii, Ho Namkoong, Takahiro Asami, Osamu Iketani, Takanori Asakura, Shoji Suzuki, Hiroaki Sugiura, Yoshitake Yamada, Tomoyasu Nishimura, Hiroshi Fujiwara, Yohei Funatsu, Yoshifumi Uwamino, Tetsuro Kamo, Sadatomo Tasaka, Tomoko Betsuyaku, Naoki Hasegawa
BACKGROUND: In multidrug regimens, including an intravenous aminoglycoside (e.g. amikacin [AMK]) is recommended for difficult-to-treat non-tuberculous mycobacterial (NTM) lung diseases. We aimed to evaluate the efficacy, safety, and feasibility of inhaled AMK therapy in patients with difficult-to-treat NTM lung diseases in a retrospective chart review. METHODS: The study population consisted of patients with NTM lung diseases who received combination therapy, including inhaled AMK therapy, at Keio University Hospital (Tokyo, Japan), from January 2014 through May 2016...
August 9, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28758820/antibacterial-activity-of-human-simulated-epithelial-lining-fluid-concentrations-of-amikacin-inhale-alone-and-in-combination-with-meropenem-against-acinetobacter-baumannii
#14
Islam M Ghazi, Mordechai Grupper, David P Nicolau
BACKGROUND: Acinetobacter baumannii(ACBN) is a MDR organism causing pneumonia in ventilated patients. High MICs often result in insufficient lung exposures, thus poor outcomes have been observed with parenteral antimicrobials. Amikacin Inhale(AMK-I), is a drug-device combination of amikacin and a Pulmonary Drug Delivery System device. We aimed to describe the pharmacodynamic profile of human simulated epithelial lining fluid(ELF) exposures of AMK-I and intravenous meropenem alone and in combination against ACBN with variable susceptibility profiles...
November 2017: Infectious Diseases
https://www.readbyqxmd.com/read/28716481/-disseminated-nocardiosis-caused-by-nocardia-nova-with-brain-abscesses-and-osteomyelitis-in-an-immunocompetent-patient
#15
P-L Conan, C Ficko, F Charton, O Bylicki, H Le Floch, J Margery, F Rivière
INTRODUCTION: Nocardia is an opportunist bacteria involved in patients with cellular immunodepression or chronic lung disease. The most frequent portals of entry are the respiratory tract by inhalation or direct inoculation through a cutaneous effraction. Nocardiosis may be localised or disseminated. CASE REPORT: We report a rare case of disseminated nocardiosis to Nocardia nova with pulmonary, cutaneous, cerebral attacks and femoral osteomyelitis. The diagnosis was confirmed by prolonged cultures of the bronchoalveolar fluid and the pus extracted from a cutaneous lesion...
January 2018: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28683216/pulmonary-drug-delivery-following-continuous-vibrating-mesh-nebulization-and-inspiratory-synchronized-vibrating-mesh-nebulization-during-noninvasive-ventilation-in-healthy-volunteers
#16
Jean-Bernard Michotte, Enrico Staderini, Anne-Sophie Aubriot, Emilie Jossen, Jonathan Dugernier, Giuseppe Liistro, Gregory Reychler
BACKGROUND: A breath-synchronized nebulization option that could potentially improve drug delivery during noninvasive positive pressure ventilation (NIPPV) is currently not available on single-limb circuit bilevel ventilators. The aim of this study was to compare urinary excretion of amikacin following aerosol delivery with a vibrating mesh nebulizer coupled to a single-limb circuit bilevel ventilator, using conventional continuous (Conti-Neb) and experimental inspiratory synchronized (Inspi-Neb) nebulization modes...
February 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/28577419/a-simplified-guide-for-charged-aerosol-detection-of-non-chromophoric-compounds-analytical-method-development-and-validation-for-the-hplc-assay-of-aerosol-particle-size-distribution-for-amikacin
#17
Arianne Soliven, Imad A Haidar Ahmad, James Tam, Nani Kadrichu, Pete Challoner, Robert Markovich, Andrei Blasko
Amikacin, an aminoglycoside antibiotic lacking a UV chromophore, was developed into a drug product for delivery by inhalation. A robust method for amikacin assay analysis and aerosol particle size distribution (aPSD) determination, with comparable performance to the conventional UV detector was developed using a charged aerosol detector (CAD). The CAD approach involved more parameters for optimization than UV detection due to its sensitivity to trace impurities, non-linear response and narrow dynamic range of signal versus concentration...
September 5, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28180105/mixed-infection-of-mycobacterium-abscessus-subsp-abscessus-and-mycobacterium-tuberculosis-in-the-lung
#18
Sungmin Sohn, Sungho Wang, Hyejin Shi, Sungrock Park, Sangki Lee, Kyoung Taek Park
A mixed infection of Mycobacterium abscessus subsp. abscessus (Mab) and Mycobacterium tuberculosis (MTB) in the lung is an unusual clinical manifestation and has not yet been reported. A 61-year-old woman had been treated for Mab lung disease and concomitant pneumonia, and was diagnosed with pulmonary tuberculosis (PTB). Despite both anti-PTB and anti-Mab therapy, her entire left lung was destroyed and collapsed. She underwent left pneumonectomy and received medical therapy. We were able to successfully treat her mixed infection by pneumonectomy followed by inhaled amikacin therapy...
February 2017: Korean Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28095918/anti-staphylococcal-activity-resulting-from-epithelial-lining-fluid-elf-concentrations-of-amikacin-inhale-administered-via-the-pulmonary-drug-delivery-system
#19
Islam M Ghazi, Mordechai Grupper, David P Nicolau
BACKGROUND: Amikacin inhale (BAY41-6551), a unique drug-device combination of a specially formulated drug solution and a pulmonary drug delivery system device (AMK-I) is currently under phase III study as an adjunctive therapy to IV antibiotics for the treatment of Gram-negative pneumonia in mechanically ventilated patients. While the epidemiology of nosocomial pneumonia is predominated by Gram-negative pathogens such as Pseudomonas aeruginosa and the Enterobacteriaceae, Staphylococcus aureus is increasingly recognized as a pathogen of concern for these pulmonary based infections...
January 17, 2017: Annals of Clinical Microbiology and Antimicrobials
https://www.readbyqxmd.com/read/27999047/efficacy-and-pharmacokinetics-of-me1100-a-novel-optimized-formulation-of-arbekacin-for-inhalation-compared-with-amikacin-in-a-murine-model-of-ventilator-associated-pneumonia-caused-by-pseudomonas-aeruginosa
#20
COMPARATIVE STUDY
Norihito Kaku, Yoshitomo Morinaga, Kazuaki Takeda, Kosuke Kosai, Naoki Uno, Hiroo Hasegawa, Taiga Miyazaki, Koichi Izumikawa, Hiroshi Mukae, Katsunori Yanagihara
Background: Arbekacin is an aminoglycoside that shows strong antimicrobial activity against Gram-positive bacteria, including MRSA, as well as Pseudomonas aeruginosa . The therapeutic effectiveness of arbekacin is directly related to C max at the infection site. To maximize drug delivery to the respiratory tract and minimize the systemic toxicity, arbekacin optimized for inhalation, ME1100, is under development. In this study, we investigated the efficacy and pharmacokinetics of ME1100 in a murine model of ventilator-associated pneumonia caused by P...
April 1, 2017: Journal of Antimicrobial Chemotherapy
keyword
keyword
62011
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"